About us
Hola Biolabs develops practical PCR solutions for laboratories introducing or simplifying molecular testing, with a commercial focus on HLA typing for rheumatology. Our portfolio combines lyophilized real-time PCR kits, compact sample-to-result systems and open qPCR compatibility, allowing laboratories to run selected HLA tests in-house or expand their existing HLA menu.
We focus on practical implementation: ready-to-use reagents, reduced manual preparation, room-temperature logistics and automation options for different testing volumes. Our current HLA direction includes markers such as HLA-B27, HLA-B51, HLA-DR4 and the HLA-DRB1 SE RA Risk Panel.
We typically work with:
- hospitals, clinics and laboratories supporting rheumatology diagnostics
- laboratories currently outsourcing HLA typing
- laboratories already running PCR
- selected distribution partners
Our mission
To help rheumatology clinics and laboratories bring HLA testing in-house and expand their HLA testing portfolio through practical assay design and flexible implementation options.
Our vision
To become a trusted partner for rheumatology laboratories implementing practical HLA testing with simple, scalable PCR-based solutions.
How we work
We do not believe molecular diagnostics should require unnecessary complexity.
That is why our solutions are designed for day-to-day use: minimal preparation steps, room-temperature-stable lyophilized reagents with no cold chain, and flexible deployment options, including automation where it makes sense.
Founders
Hola Biolabs was founded by Jan Drápal and Atal Baryal.
The company is built on the conviction that a focused team can create real value by staying close to real laboratory needs and prioritizing practical execution.
Our story
Hola Biolabs was founded in 2020 in Brno, Czech Republic during the COVID-19 pandemic.
We started with PCR assay development and operated our own diagnostic laboratory. During that period, we performed more than 200,000 tests and saw first-hand what makes molecular testing difficult to implement and run in everyday practice.
That experience shaped how we approach product development. Instead of adding complexity, we focused on making PCR testing easier to deploy and easier to run. This led us to lyophilized assay formats designed to better fit routine laboratory conditions.
Over time, we applied this approach to HLA typing — an area where many laboratories still rely on send-out testing.
Today, we focus on helping laboratories bring HLA testing in-house or simplify existing PCR set-ups, using solutions designed for real laboratory use.